Abstract：
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is a significant cause of mortality, with its prevalence projected to rise in Asia. The primary objective of this study was to describe clinical characteristics, maintenance treatment, and healthcare resource utilization (HCRU) among patients with COPD in Hong Kong. Secondary objectives were to assess patient demographics and clinical characteristics by eosinophil (EOS) levels, and compare the demographics, clinical characteristics, and treatment patterns of patients on multiple-inhaler triple therapy (MITT).
METHODS: This study analyzed a cohort of patients with COPD who had entered a previously initiated prospective cohort study involving patients with COPD and/or asthma at the Prince of Wales Hospital between 2017 and 2019.
RESULTS: Patients with COPD were enrolled (N = 220, mean age 74.3 years, 97 % male). Twelve months prior to baseline assessment, 66 % of patients were on MITT, 17 % on long-acting muscarinic antagonists (LAMAs)/long-acting beta-agonists (LABAs), and 7 % on inhaled corticosteroids (ICS)/LABA. Compared with ICS/LABA or LAMA/LABA, more patients on MITT experienced ≥1 exacerbation (26.7 %, 10.5 %, 39.7 %, respectively). Patients on MITT also had a higher mean (SD) COPD Assessment Test score (9.4 [5.9]) and modified Medical Research Council Dyspnea Scale score (1.7 [0.7]) and incurred the most COPD-related and total HCRU costs. Compared with patients with EOS ≤300 cells/μL, those with EOS >300 cells/μL had a higher number of exacerbations.
CONCLUSIONS: Patients with COPD in Hong Kong treated with MITT presented more severe disease profiles and incurred higher costs. These data can be used for decision making in patients with moderate-to-severe COPD in Hong Kong.
METHODS: This study analyzed a cohort of patients with COPD who had entered a previously initiated prospective cohort study involving patients with COPD and/or asthma at the Prince of Wales Hospital between 2017 and 2019.
RESULTS: Patients with COPD were enrolled (N = 220, mean age 74.3 years, 97 % male). Twelve months prior to baseline assessment, 66 % of patients were on MITT, 17 % on long-acting muscarinic antagonists (LAMAs)/long-acting beta-agonists (LABAs), and 7 % on inhaled corticosteroids (ICS)/LABA. Compared with ICS/LABA or LAMA/LABA, more patients on MITT experienced ≥1 exacerbation (26.7 %, 10.5 %, 39.7 %, respectively). Patients on MITT also had a higher mean (SD) COPD Assessment Test score (9.4 [5.9]) and modified Medical Research Council Dyspnea Scale score (1.7 [0.7]) and incurred the most COPD-related and total HCRU costs. Compared with patients with EOS ≤300 cells/μL, those with EOS >300 cells/μL had a higher number of exacerbations.
CONCLUSIONS: Patients with COPD in Hong Kong treated with MITT presented more severe disease profiles and incurred higher costs. These data can be used for decision making in patients with moderate-to-severe COPD in Hong Kong.
摘要：
目的：慢性阻塞性肺疾病（COPD）是死亡的重要原因，预计其在亚洲的流行率将上升。这项研究的主要目的是描述临床特征，维持治疗,以及香港慢性阻塞性肺疾病患者的医疗资源利用(HCRU)。次要目标是通过嗜酸性粒细胞（EOS）水平评估患者的人口统计学和临床特征，比较人口统计，临床特征,多吸入器三联疗法（MITT）患者的治疗模式。
方法：本研究分析了2017-2019年间在威尔士亲王医院进行的一项前瞻性队列研究的COPD患者队列。
结果：纳入COPD患者（N=220，平均年龄74.3岁，97%男性）。基线评估前12个月，66%的患者接受了MITT,17％的长效毒蕈碱拮抗剂（LAMA）/长效β-激动剂（LABA），吸入性皮质类固醇（ICS）/LABA为7％。与ICS/LABA或LAMA/LABA相比，更多的MITT患者经历了≥1次加重(26.7%，10.5%,39.7%,分别)。接受MITT的患者的平均（SD）COPD评估测试评分（9.4[5.9]）和改良的医学研究理事会呼吸困难量表评分（1.7[0.7]）也较高，并且发生的COPD相关费用和HCRU总成本最高。与EOS≤300细胞//μL的患者相比，EOS>300个细胞//μL的患者加重次数较多.
结论：在香港，接受MITT治疗的COPD患者病情更为严重，费用更高。这些数据可用于香港中重度COPD患者的决策。
方法：本研究分析了2017-2019年间在威尔士亲王医院进行的一项前瞻性队列研究的COPD患者队列。
结果：纳入COPD患者（N=220，平均年龄74.3岁，97%男性）。基线评估前12个月，66%的患者接受了MITT,17％的长效毒蕈碱拮抗剂（LAMA）/长效β-激动剂（LABA），吸入性皮质类固醇（ICS）/LABA为7％。与ICS/LABA或LAMA/LABA相比，更多的MITT患者经历了≥1次加重(26.7%，10.5%,39.7%,分别)。接受MITT的患者的平均（SD）COPD评估测试评分（9.4[5.9]）和改良的医学研究理事会呼吸困难量表评分（1.7[0.7]）也较高，并且发生的COPD相关费用和HCRU总成本最高。与EOS≤300细胞//μL的患者相比，EOS>300个细胞//μL的患者加重次数较多.
结论：在香港，接受MITT治疗的COPD患者病情更为严重，费用更高。这些数据可用于香港中重度COPD患者的决策。
